ClinicalTrials.gg
RecruitingNCT05967403Updated Apr 27, 2026

Performance Analysis of Hermetic Closed-loop Anesthesia Delivery System

An interventional study of Propofol and Propofol in Anesthesia, sponsored by Sir Ganga Ram Hospital. Recruiting at 1 site in India. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-27.

Sponsored by Sir Ganga Ram Hospital · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Total intravenous anaesthesia (TIVA) is now a preferred technique for providing general anaesthesia (GA) because of its various inherent advantages like reduced postoperative nausea and vomiting (PONV), improved quality of post-operative recovery, anti-inflammatory and antioxidant action, anti-neoplastic activity, analgesic action, and absence of greenhouse effect. The evolution and advancement in automated anaesthesia delivery systems particularly for propofol have made propofol-TIVA more efficient by removing the human interface for both rate and concentration adjustments. Automated computer-controlled closed loop anaesthesia device adjusts propofol delivery based on patient's frontal cortex electrical activity determined by bispectral index (BIS).

Closed loop anaesthesia delivery system (CLADS) is an indigenously developed patented (Patent no.502/DEL/2003 \& US 9,108,013 B2) computer-controlled anaesthesia delivery system which works with feedback loop information elicited by BIS monitoring and delivers propofol TIVA to the patient via a non-TCI automated infusion pump. It has been an extensively used and validated in patients undergoing both cardiac and non-cardiac surgical procedures.

A new compact and upgraded version of CLADS is now available. This new version incorporates the anesthetic depth monitor, hemodynamic monitor, controller, user interface and actuator syringe pump into a single, compact and user-friendly module.

The investigators aim to conduct a prospective randomized pilot study comparing the new CLADS and older CLADS version with respect to: adequacy of anaesthesia depth maintenance, performance characteristic of propofol delivery system, propofol requirement, haemodynamics stability, recovery from anesthesia and postoperative sedation.

Read the detailed description

Propofol total intravenous anaesthesia (TIVA) is a preferred technique for providing induction and maintenance of general anaesthesia (GA). As opposed to the conventional inhaled anesthetics for maintaining GA, propofol TIVA has several advantages, such as, lower incidence of postoperative nausea and vomiting (PONV), antinociceptive and anti-inflammatory action, anti-neoplastic activity, and most importantly, its environment disposition (no greenhouse effect); and therefore, has potential to replace inhaled vapors for GA.

The introduction of target-controlled infusion (TCI) pumps has allowed precision control in propofol delivery as compared to the conventional manually operated infusion pumps. In manually operated infusion pumps the clinician regulates the propofol infusion rate to achieve the desired anaesthesia depth, whereas TCI-pumps deliver propofol using inbuilt algorithms based on the pharmacokinetic (PK) and pharmacodynamic (PD) profile of propofol. Two of the most used PK-PD models for propofol delivery are the Marsh model and the Schneider model. Whereas in the Marsh model the user can set the desired target plasma concentration, Schneider model allows the user to set the desired target effect site concentration for achieving adequate depth of GA.

Over the last two decades the evolution and advancement in automated anaesthesia delivery systems, particularly for propofol administration, has made propofol-TIVA delivery more efficient by removing the human interface required for adjusting real-time propofol delivery, both rate and concentration of propofol. Automated anaesthesia delivery systems deliver propofol based on ascertaining frontal cortex electrical activity as determined by the processed electroencephalogram, the bispectral index (BIS) score. These devices regulate propofol delivery based on a feedback loop involving the BIS score (control variable) generated by the patient and the propofol infusion pump (actuator) and attempts to keep the values within a pre-assigned range, consistent with robust GA depth.

Closed loop anaesthesia delivery system (CLADS) is an indigenously developed patented (Patent no.502/DEL/2003 \& US 9,108,013 B2) computer-controlled anaesthesia delivery system which works with feedback loop information elicited by BIS monitoring and delivers propofol TIVA to the patient via a non-TCI automated infusion pump. The basic control algorithm is based on the relationship between the infusion rates of propofol and BIS values, taking into consideration the pharmacokinetic variables, such as, drug distribution and clearance. The system updates the EEG data every 5-seconds and calculates the BIS error, a difference between the target BIS and the actual BIS value using the proportional-integral-derivative (PID) controller. During anaesthesia induction the target concentration is achieved in a stepwise manner with BIS feedback received every 5-seconds. During maintenance phase of anaesthesia, the propofol delivery is modified every 1-epoch of 30-seconds duration. In each epoch an average of initial 3-BIS values (of every 5-seconds) and average of last 3-BIS values (of every 5-seconds) are compared, and a trend assessment is made. If the trend indicates increasing BIS values, then higher propofol rate is delivered by the infusion pump (actuator) and vice-versa. The control algorithm is implemented using a personal computer (PC) with a Pentium 4 processor. The PC controls communication with the infusion pump (Pilot-C, Fresenius, Paris, France) and the vital sign monitor (AS5, Datex Ohmeda Division, GE Healthcare, Singapore) through RS 232 serial ports.

CLADS has been extensively used and validated for administering propofol TIVA in patients undergoing both cardiac and non-cardiac surgical procedures. In a multi-centric study on evaluation of anaesthesia delivery by CLADS, it was shown that CLADS maintains depth of anaesthesia with far more precision as compared to manual administration.

A new compact and upgraded version of CLADS (Clarity Medical Private Ltd., Mohali, Punjab Indiais now available. The new version integrates the anaesthetic depth as well as the hemodynamic monitor, the controller, the user interface and the actuator syringe pump into a single, compact and user-friendly module.

The investigators aim to conduct a prospective randomised pilot to compare the multiple connected-unit conventional CLADS with the hermetically unit-integrated CLADS version, with respect to, the adequacy of anaesthesia depth (primary objective); and, performance characteristic, propofol requirement, haemodynamic stability, recovery from anaesthesia and postoperative sedation of the delivery systems (secondary objectives).

02

Conditions studied

  • Anesthesia

Keywords

  • propofol
  • closed-loop
  • anesthesia
03

In context

Lead sponsor

Sir Ganga Ram Hospital is the lead sponsor of 30 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • aged 18-65 years-
  • I-II
  • undergoing elective non-cardiac surgery of minimum 60-minutes duration

Exclusion criteria

Exclusion Criteria:

  • Uncompensated cardiovascular disease (e.g., uncontrolled hypertension, atrio- ventricular block, sinus bradycardia, congenital heart disease, reduced LV compliance, diastolic dysfunction).
  • Hepato-renal insufficiency.
  • Any history of neurological disorder (e.g., epilepsy) or brain trauma
  • Uncontrolled endocrine diseases (e.g., diabetes mellitus, hypothyroidism).
  • Known allergy/ to the study drug.
  • History of any psychiatric disorder and/or drug dependence/substance abuse.
  • Requirement of postoperative ventilation.
  • Refusal to .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Active comparator
    Conventional CLADS group

    Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the conventional (prototype) closed-loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anesthesia

    Drug: Propofol

  • Active comparator
    Hermetic CLADS group

    Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the hermetic closed-loop anaesthesia delivery system (CLADS).\[(Clarity Medical Private Ltd., Mohali, Punjab India\]. A BIS value of 50 will be used as the target point for induction and maintenance of anesthesia

    Drug: Propofol

Interventions

  • Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the conventional closed loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.

  • Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the hermetic closed loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.

06

What researchers measure

Primary outcomes

  1. Anaesthesia depth consistency

    It will be determined by the percentage of the anaesthesia time during which the BIS remained +/- 10 of the target BIS of 50

    Time frame: From beginning of anaesthesia till 5- minutes post skin closure

Secondary outcomes

  1. Performance characteristic of propofol delivery system

    It will be determined using the Varvel criteria parameter :median performance error (MDPE). This parameter is calculated by the computer software which analyses the intraoperative BIS data. This parameter have no unit of measurement. It's just an abstract number. Higher the value means worse performance of propofol delivery system. It is not a scale.

    Time frame: From beginning of anaesthesia till 5- minutes post skin closure

  2. Performance characteristic of propofol delivery system

    It will be determined using the Varvel criteria parameter: median absolute performance error (MDAPE).This parameter is calculated by the computer software which analyses the intraoperative BIS data. This parameter have no unit of measurement. Its just a abstract number.Higher the value means worse performance of propofol delivery system. It is not a scale.

    Time frame: From start of anesthesia till 5- minutes post skin closure

  3. Performance characteristic of propofol delivery system

    It will be determined using the Varvel criteria parameter: wobble. This parameter is calculated by the computer software which analyses the intraoperative BIS data. This parameter have no unit of measurement. Its just a abstract number.Higher the value means worse performance of propofol delivery system. It is not a scale.

    Time frame: From start of anesthesia till 5- minutes post skin closure

  4. Performance characteristic of propofol delivery system

    It will be determined using the Varvel criteria parameter: global score. It is calculated using the formula Median absolute performance error + wobble / percentage of the anesthesia time during which the BIS remained +/- 10 of the target BIS of 50. This parameter have no unit of measurement. Its just a abstract number.Higher the value means worse performance of propofol delivery system. It is not a scale.

    Time frame: From start of anesthesia till 5- minutes post skin closure

  5. . Propofol induction dose (mg/kg)

    Dose of propofol required for induction of anaesthesia

    Time frame: From start of propofol injection till 10-minutes intraoperatively

  6. . Propofol maintenance dose (mg/kg/h)

    Dose of propofol required for maintenance of anaesthesia

    Time frame: From start of propofol injection till 5-minutes post skin closure

  7. Time to loss of consciousness (measured in minutes)

    The time taken (in minutes) from starting propofol induction using CLADS till loss of verbal response.

    Time frame: From start of propofol injection till 10-minutes intraoperatively

  8. Time to induction of anaesthesia (measured in minutes)

    The time taken (in minutes) from starting propofol induction using CLADS till a target BIS value of '50' is achieved

    Time frame: From start of propofol injection till 10-minutes intraoperatively

  9. Intra-operative heart Rate (beats per minute)

    Comparison of intra-operative heart rate between the study arms will be done

    Time frame: From beginning of anaesthesia till 10 hours intraoperatively]

  10. Intra-operative systolic , diastolic, and mean blood pressure (mmHg)

    Comparison of intra-operative blood pressure- systolic, diastolic, and mean blood pressure between the study arms will be done

    Time frame: From beginning of anaesthesia till 10 hours intraoperatively]

  11. Early recovery from anaesthesia (measured in minutes)

    Time taken by the patient to open his/her eyes after discontinuation of anaesthesia will be noted

    Time frame: From end of anaesthesia till 20-minutes postoperatively

  12. Early recovery from anaesthesia (measured in minutes)

    Time taken for tracheal extubation after discontinuation of anaesthesia will be noted

    Time frame: From end of anaesthesia till 20-minutes postoperatively

  13. Postoperative sedation

    Will be assessed using Modified Observer's assessment of alertness/sedation scale. The scale has a maximum value of '5', which refers to a fully awake patient and a minimum value of '0' which refers to a deeply sedated patient.

    Time frame: From end of anaesthesia till 24-hours postoperatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Oct 2026, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2023
First posted
Aug 1, 2023
StartActual
Dec 9, 2023
Primary completionEst.
Oct 2026
CompletionEst.
Nov 2026
Last update
Apr 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05967403
Lead sponsor
Sir Ganga Ram Hospital
Responsible party
Nitin Sethi, DNB (Senior Consultant, Institute of Anaesthesiology, Pain & Perioperative Medicine, Sir Ganga Ram Hospital) — Principal investigator
First posted
Aug 1, 2023
Start date
Dec 9, 2023
Primary completion
Oct 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Apr 27, 2026

Study contacts

Amitabh Dutta, MD, PGDHR
Contact
duttaamitabh@yahoo.co.in
+919810848064
Nitin Sethi, DNB
Contact
nitinsethi77@yahoo.co.in
+919717494498
Nitin Sethi, DNB
study director · Sir Ganga Ram Hospital, New Delhi, INDIA
Amitabh Dutta, MD, PGDHR
principal investigator · Sir Ganga Ram Hospital, New Delhi, INDIA
Goverdhan D Puri, MD, PhD
study chair · Post Graduate Institute of Medical Education & Research, Chandigarh, India

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Propofol

Start the discussion